Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00469-1425-90 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Nov 29, 2018 In Use
00469-1425-21 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 30, 2022 In Use
72237-0102-02 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0102-06 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0101-02 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jul 10, 2019 In Use
72237-0101-03 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jun 22, 2020 In Use
72237-0102-07 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0101-05 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jul 10, 2019 In Use
72237-0101-01 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jul 10, 2019 In Use
72237-0103-05 72237-0103 selinexor XPOVIO 50.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0101-06 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jun 22, 2020 In Use
72237-0104-01 72237-0104 selinexor XPOVIO 60.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0101-04 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jul 10, 2019 In Use
72237-0101-07 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jun 22, 2020 In Use
00469-0125-99 00469-0125 Enzalutamide Xtandi 40.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug 31, 2012 In Use
00469-1725-56 00469-1725 Enzalutamide Xtandi 40.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug 4, 2020 In Use
00469-0725-60 00469-0725 enzalutamide Xtandi 80.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug 4, 2020 In Use
00469-0625-99 00469-0625 enzalutamide Xtandi 40.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug 4, 2020 In Use
00003-2328-22 00003-2328 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Mar 25, 2011 In Use
00003-2327-11 00003-2327 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Mar 25, 2011 In Use
71287-0119-02 71287-0119 Axicabtagene ciloleucel Yescarta 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 18, 2017 In Use
59676-0610-01 59676-0610 Trabectedin Yondelis 0.05 mg/mL Chemotherapy Alkylating Agent Natural Product Intravenous Oct 23, 2015 In Use
47335-0401-81 47335-0401 abiraterone acetate YONSA 125.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 22, 2018 In Use
00024-5841-01 00024-5841 ziv-Aflibercept Zaltrap 200.0 mg/8mL, 200.0 mg/8mL Chemotherapy Recombinant Fusion Protein VEGF-IgG1 Intravenous Aug 3, 2012 In Use
00024-5840-03 00024-5840 ziv-Aflibercept Zaltrap 100.0 mg/4mL Chemotherapy Recombinant Fusion Protein VEGF-IgG1 Intravenous Aug 3, 2012 Nov 27, 2019 In Use

Found 11120 results — Export these results